JP2008537727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008537727A5 JP2008537727A5 JP2007554182A JP2007554182A JP2008537727A5 JP 2008537727 A5 JP2008537727 A5 JP 2008537727A5 JP 2007554182 A JP2007554182 A JP 2007554182A JP 2007554182 A JP2007554182 A JP 2007554182A JP 2008537727 A5 JP2008537727 A5 JP 2008537727A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- antagonist
- receptor
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64928705P | 2005-02-01 | 2005-02-01 | |
| US60/649,287 | 2005-02-01 | ||
| PCT/US2006/003519 WO2006083947A2 (en) | 2005-02-01 | 2006-02-01 | Compositions and methods for treating fibrotic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008537727A JP2008537727A (ja) | 2008-09-25 |
| JP2008537727A5 true JP2008537727A5 (enExample) | 2009-03-19 |
| JP5231814B2 JP5231814B2 (ja) | 2013-07-10 |
Family
ID=36575858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554182A Expired - Lifetime JP5231814B2 (ja) | 2005-02-01 | 2006-02-01 | 線維性障害を治療するための組成物および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20060171943A1 (enExample) |
| EP (1) | EP1843789B1 (enExample) |
| JP (1) | JP5231814B2 (enExample) |
| AT (1) | ATE503495T1 (enExample) |
| AU (1) | AU2006210848B2 (enExample) |
| CA (1) | CA2595786C (enExample) |
| CY (1) | CY1111577T1 (enExample) |
| DE (1) | DE602006020982D1 (enExample) |
| DK (1) | DK1843789T3 (enExample) |
| ES (1) | ES2363162T3 (enExample) |
| HR (1) | HRP20110319T1 (enExample) |
| MX (1) | MX2007009235A (enExample) |
| PL (1) | PL1843789T3 (enExample) |
| PT (1) | PT1843789E (enExample) |
| RS (1) | RS51704B (enExample) |
| SI (1) | SI1843789T1 (enExample) |
| WO (1) | WO2006083947A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8114964B2 (en) * | 2005-05-19 | 2012-02-14 | Centocor, Inc. | Anti-MCP-1 antibodies, compositions, methods and uses |
| KR101363777B1 (ko) * | 2005-09-30 | 2014-02-14 | 메디뮨 리미티드 | 인터루킨―１３ 항체 조성물 |
| GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| AR064333A1 (es) | 2006-12-14 | 2009-04-01 | Schering Corp | Anticuerpo anti-tslp de diseno |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| DK2164514T3 (en) * | 2007-05-21 | 2017-02-27 | Alderbio Holdings Llc | Antibodies to IL-6 and its use |
| NZ601583A (en) * | 2007-05-21 | 2013-08-30 | Bristol Myers Squibb Co | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| KR20100034015A (ko) | 2007-06-20 | 2010-03-31 | 아이알엠 엘엘씨 | 알레르기 질환 치료를 위한 방법 및 조성물 |
| EP2342340A1 (en) | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| US8323649B2 (en) * | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| EP2213682A1 (en) | 2009-01-30 | 2010-08-04 | Institut Curie | TSLP promotes immune evasion and persistence of viruses |
| EP3594356A1 (en) | 2009-11-04 | 2020-01-15 | Merck Sharp & Dohme Corp. | Engineered anti-tslp antibody |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| EP2504032A4 (en) | 2009-11-24 | 2013-06-19 | Alderbio Holdings Llc | IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS |
| CA2794189C (en) | 2010-03-24 | 2022-01-11 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
| US9095504B2 (en) | 2010-03-24 | 2015-08-04 | Rxi Pharmaceuticals Corporation | RNA interference in ocular indications |
| US8992908B2 (en) | 2010-11-23 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of oral mucositis |
| WO2015085113A1 (en) * | 2013-12-04 | 2015-06-11 | Rxi Pharmaceuticals Corporation | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
| EA038332B1 (ru) | 2015-09-09 | 2021-08-10 | Новартис Аг | Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул |
| EP3842457A1 (en) | 2015-09-09 | 2021-06-30 | Novartis AG | Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules |
| CN114887053B (zh) * | 2019-11-29 | 2026-04-24 | 康诺亚生物医药科技（成都）有限公司 | 一种tslp相关病症治疗剂的开发和应用 |
| TWI915520B (zh) * | 2021-03-03 | 2026-02-21 | 大陸商正大天晴藥業集團股份有限公司 | 含抗tslp抗體的藥物組合物 |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| WO2024226993A1 (en) * | 2023-04-28 | 2024-10-31 | Prana Therapies, Inc. | Tslp inhibitors and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995000103A2 (en) * | 1993-06-15 | 1995-01-05 | Il-Yang Pharm. Co., Ltd. | Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof |
| GB9702944D0 (en) * | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
| US6844170B1 (en) * | 1998-03-19 | 2005-01-18 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
| US20030099947A1 (en) * | 1998-09-21 | 2003-05-29 | Bazan J. Fernando | Mammalian cytokines; related reagents and methods |
| CA2349762C (en) * | 1998-11-13 | 2013-12-24 | Immunex Corporation | Human tslp dna and polypeptides |
| US7964713B2 (en) * | 2000-06-28 | 2011-06-21 | Amgen Inc. | Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof |
| MXPA04007426A (es) * | 2002-02-01 | 2004-10-11 | Schering Corp | Usos de citosina de mamifero; reactivos relacionados. |
| US20050249712A1 (en) * | 2004-03-23 | 2005-11-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for use of TSLP and agonists and antagonists thereof |
| CA2577631A1 (en) * | 2004-08-20 | 2006-03-02 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
-
2006
- 2006-01-31 US US11/344,379 patent/US20060171943A1/en not_active Abandoned
- 2006-02-01 EP EP06720055A patent/EP1843789B1/en not_active Expired - Lifetime
- 2006-02-01 AT AT06720055T patent/ATE503495T1/de active
- 2006-02-01 RS RS20110198A patent/RS51704B/sr unknown
- 2006-02-01 DE DE602006020982T patent/DE602006020982D1/de not_active Expired - Lifetime
- 2006-02-01 JP JP2007554182A patent/JP5231814B2/ja not_active Expired - Lifetime
- 2006-02-01 WO PCT/US2006/003519 patent/WO2006083947A2/en not_active Ceased
- 2006-02-01 SI SI200630971T patent/SI1843789T1/sl unknown
- 2006-02-01 PT PT06720055T patent/PT1843789E/pt unknown
- 2006-02-01 ES ES06720055T patent/ES2363162T3/es not_active Expired - Lifetime
- 2006-02-01 AU AU2006210848A patent/AU2006210848B2/en not_active Expired
- 2006-02-01 HR HR20110319T patent/HRP20110319T1/hr unknown
- 2006-02-01 MX MX2007009235A patent/MX2007009235A/es active IP Right Grant
- 2006-02-01 PL PL06720055T patent/PL1843789T3/pl unknown
- 2006-02-01 CA CA2595786A patent/CA2595786C/en not_active Expired - Lifetime
- 2006-02-01 DK DK06720055.0T patent/DK1843789T3/da active
-
2011
- 2011-01-24 US US13/012,745 patent/US20110117053A1/en not_active Abandoned
- 2011-06-21 CY CY20111100587T patent/CY1111577T1/el unknown
-
2016
- 2016-10-05 US US15/285,949 patent/US20170081668A1/en not_active Abandoned
-
2019
- 2019-03-18 US US16/356,807 patent/US20190203209A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110319T1 (hr) | Smjese i metode liječenja fibroznih poremećaja | |
| Bendtzen | Cytokines and natural regulators of cytokines | |
| Luo et al. | Distinct spatial and temporal roles for Th1, Th2, and Th17 cells in asthma | |
| Caramori et al. | Cytokine inhibition in the treatment of COPD | |
| Nakajima et al. | Role of IL-23 and Th17 cells in airway inflammation in asthma | |
| Belperio et al. | The role of cytokines during the pathogenesis of ventilator-associated and ventilator-induced lung injury | |
| Vercelli et al. | Regulation of IgE synthesis in humans | |
| Lebel-Binay et al. | Interleukin-18: biological properties and clinical implications | |
| Kaiser et al. | Avian cytokines and chemokines | |
| Takatsu | Interleukin-5 and IL-5 receptor in health and diseases | |
| Di Padova et al. | Selective and early increase of IL‐1 inhibitors, IL‐6 and cortisol after elective surgery | |
| Wang et al. | Cytokines frequently implicated in myeloproliferative neoplasms | |
| Izuhara et al. | Recent developments regarding periostin in bronchial asthma | |
| Heck et al. | Pharmacological therapy of bronchial asthma: the role of biologicals | |
| Miyajima | Molecular structure of the IL-3, GM-CSF and IL-5 receptors | |
| JP2009523460A5 (enExample) | ||
| Pauwels et al. | Cytokine manipulation in animal models of asthma | |
| Takatsu | Cytokines involved in B-cell differentiation and their sites of action | |
| JP2011508592A5 (enExample) | ||
| RU2010149746A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| Hata et al. | IL-18 together with anti-CD3 antibody induces human Th1 cells to produce Th1-and Th2-cytokines and IL-8 | |
| US6890734B2 (en) | Nucleic acids encoding a cytokine receptor complex | |
| Watanabe et al. | Monoclonal antibody against the common beta subunit (beta c) of the human interleukin-3 (IL-3), IL-5, and granulocyte-macrophage colony-stimulating factor receptors shows upregulation of beta c by IL-1 and tumor necrosis factor-alpha | |
| RU2003114746A (ru) | Модифицированное агонистическое антитело | |
| Bhandari | Developmental differences in the role of interleukins in hyperoxic lung injury in animal models |